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Animal models have been broadly used in the study of pathophysiology and 
molecular and neurochemical pathways in neuropsychiatric diseases. Different 
approaches have used both consanguineous and non-consanguineous mice 
models to model behavioral patterns associated with the maniac spectrum. 
However, the disadvantages of validating clinical and experimental protocols have 
hindered the replication of these studies. In this article, the advantages and 
disadvantages of using consanguineous lines and non-consanguineous stocks in 
mice animal models for the study of mania and its subtypes are discussed. 
Additionally, new experimental alternatives to advance the pathogenesis and 
pharmacogenetics of mania using animal models are proposed and analyzed 
 
RESUMEN   
 
Palabras clave: 
modelos animales, 
trastorno afectivo 
bipolar, knockout y 
manía. 
Los modelos animales se han utilizado ampliamente en el estudio de la 
fisiopatología y vías moleculares y neuroquímicos en enfermedades 
neuropsiquiátricas. Diferentes enfoques han utilizado modelos de ratones 
consanguíneos y no consanguíneos para modelar patrones de comportamiento 
asociados con el espectro maníaco. Sin embargo, las desventajas de la validación 
de los protocolos clínicos y experimentales han obstaculizado la replicación de 
estos estudios. En este artículo, se discuten las ventajas y desventajas del uso de 
líneas consanguíneas y no consanguíneas en modelos animales de ratones para 
el estudio de la manía y sus subtipos. Además, se proponen y analizan las nuevas 
alternativas experimentales para avanzar en la patogénesis y la farmacogenética 
de la manía utilizando modelos animales. 
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1. INTRODUCTION 
 
The understanding of bipolar disorder has had 
substantial changes in the last 10 years. Currently, our 
concept of mania and especially manic states has 
included a great variety of symptoms which can 
contribute to the clinical discrimination of the presence 
of subtypes and thus delineate differential diagnoses 
within bipolar spectrum disorders. Even though the 
presence of mania can derive from viral infections, 
head trauma and other neurological conditions, its 
expression is also narrowly related to bipolar disorder. 
Our analysis begins with and aims to deepen the 
understanding of this disorder. 
Bipolar disorder affects 1 to 4% of the general 
population and has been frequently associated with 
high rates of mortality and morbidity (Saunders and 
Geddes 2016). This situation is reflected in the study 
performed by Fiona J Charlson et al in 2016, which 
shows high mortality rates in bipolar patients (Charlson, 
et al. 2016). This can be explained in large part due to 
the high prevalence of bipolar disorder worldwide, with 
58.9 million cases reported by 2010 (Degenhardt, et al. 
2013). 
Mania is generally characterized by the 
presence of an abnormally euphoric and exalted mood 
state. In addition, for manic patients irritability, 
distractibility and inhibitory control failures significantly 
affect the performance of daily activities. In many 
cases, the impact on functionality is unfortunate and 
can lead to negative effects in both the social and 
cognitive performance of these patients. Particularly in 
type I Bipolar Disorder, in which mania predominates, 
the combination of the disorder with functional deficits 
related to disruptive conduct leads to neurocognitive 
changes, specifically a deterioration in executive 
functions such as processing speed, executive 
attention, work memory, and decision-making.  
Although new clinical intervention strategies to control 
or reduce bizarre  behavior do exist, approaches that 
address cognitive dysfunction in Bipolar Disorder are 
still limited (Bora, et al. 2016; Cotrena, et al. 2016; 
McCormack, et al. 2016). 
Different personalized medicinal alternatives to 
treat the symptoms of manic episodes have recently 
been developed: clinical instruments that refine the 
manic spectrum; advances in pharmacogenetics based 
on the use of computational models to discern 
molecular biology; and advances in our understanding 
of metabolic pathways and the kinetic properties of 
medication used for the treatment of mania. The latter 
has the aim of recognizing the neurophysiological 
significance of the molecules that play an important part 
in the manic spectrum. 
In this context, the use of animal models in the 
study of mania was initially crucial to prioritizing 
pharmacological strategies. The first approaches were 
conducted on mice with the use of psychostimulants to 
increase motor activity as one of the observable 
behaviors present in mania.  However, and particularly 
in the use of stimulants, the phenotype related to 
increased motor activity is shared with other clinical 
phenotypes like anxiety and drug abuse, conditions 
which were not found to be sufficiently consistent to 
validate an animal model with this phenotype for mania.  
In this article, we analyze the phenotypes that were 
found to be potentially informative in rodents, and that 
could contribute to the modeling of neurobiological 
pathways in mania. This analysis is directed towards 
finding new therapeutic targets and allowing the 
discrimination of different subtypes of bipolar disorder. 
 
2. ANIMAL MODELS  
 
The use of rodents has sped up the 
development of potential therapeutic objectives in 
different diseases. Furthermore, in the study of 
behavior it has established an experimental preference 
matrix to model illnesses related to psychiatric 
disorders. In laboratories, two types of genetically 
defined mice models have been used. Consanguineous 
lines, as a prototype of genetically standardized lines, 
allow control over the genetic constitution of individuals 
(Chow 2016), eliminating the inconveniences of 
populational stratification and encouraging genetic 
homogeneity in the model. Additionally, laboratories 
have monitored endogamy levels and supervised 
endogamic depression (which can lead to the loss of 
the line or impact the adaptation of the animals to their 
environment, affecting the behaviors of interest). 
Consanguineous lines have guided 
researchers toward different potential targets with 
pharmacogenetic therapeutic purposes because allele 
fixations set an ideal genetic scenario for the evaluation 
of the association between drugs and allelic variants 
due to the isogenicity of the lines. Therefore, different 
studies that aim to improve the efficacy of 
pharmacology in treating bipolar disorder have used 
consanguineous lines. Knockout mice (KO) have been 
a promising alternative. These mice are modified by 
genetic engineering and allow the identification of the 
role of a particular gene based on the identification of 
its amino acid sequence in its etiopathogenesis or in the 
action mechanisms of various drugs with unknown 
functions. For example, to determine the 
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pathophysiological impact of Glycogen synthase kinase 
3beta (GSK 3beta) on KO mice, the potential of new 
GSK-3 inhibitors were evaluated using the 
consanguineous line C57BL, one of the most used by 
comparative genomics and the line chosen by the 
International Mouse Sequencing Consortium for the 
sequencing of the murine genome. GSK-3beta is a 
serine/threonine protein kinase with high concentration 
in the brain, where it modulates gene expression and 
neural plasticity among other neurodevelopment 
processes (Frame and Cohen 2001; Furlotti, et al. 
2015). Recent studies suggest that the inhibition of 
GSK3beta through the increase of serine 
phosphorylation modulates the pharmacological 
response and reduces observable hyperactive 
behavior in this model. This is similar to the response 
to lithium which also increases serine phosphorylation 
and reduces the antimanic response (Li et al. 2010). On 
the other hand, KO mice have also been used in 
attempts to modulate hyperactivity and homogenize the 
accelerated motors of the mice and control the 
uninhibited and disorganized behavior of the manic 
phase. From this perspective, DGKη-knockout was 
used to determine how the function of diacylglycerol 
kinase (DGK) is related to the neurogenic mechanisms 
involved in mania and illuminated its important role in 
cognitive function, particularly in memory and emotional 
regulation. Nevertheless, the molecular pathways that 
underlie the clinical expressions related to mania and 
could be associated with the differential expression of 
DGK have not yet been determined (Isozaki, et al. 
2016). 
The mice line Dab1 has been used similarly to 
explore the neurophysiopathology of the manic 
spectrum. Dab1 is an intracellular adaptive protein 
involved in signal processes and neuronal function 
linked to Reelin, a cellular migration glycoprotein that 
promotes the maturation of dendritic spines and also 
contributes to synaptic modulation and memory 
function (Jacquelin, et al. 2013). The Reelin-Dab1 
complex is key to both motor function and the 
expression of social conduct. Currently, alterations in 
motor function, spatial memory, and contextual fear 
memory have been observed in Knockout Dab1 mice. 
Additionally, a decrease in the expression of Reelin-
Dab1 complex in the cerebral cortex produces strange 
behavior as well as learning and memory deficits (Imai, 
et al. 2016). Perhaps one of the most robust 
approaches to modelling a behavioral pattern related to 
the manic spectrum came from studies that 
implemented the chronic administration of stimulants 
such as amphetamine (AMPH), which was able to 
produce an effect on the inhibition of dopamine 
reuptake (Fries, et al. 2015; Macedo, et al. 2012). To 
determine how long term treatment with AMPH could 
be involved in the pathogenesis of mania, Gubert et al. 
used KO for the purinergic receptor P2X7R. 
Purinoreceptors are present in cells of the immune 
system and are widely distributed in nerve terminals, 
affecting the release of neurotransmissors like 
glutamate or GABA, and constitute a modulating agent 
in the concentration of intracellular calcium.  With this 
line researchers were able to determine that there was 
a significant increase in motor activity and establish a 
proinflammatory response associated with the 
presence of cognitive deterioration in functions like 
work memory and processing speed in patients with 
bipolar disorder (Cuartas 2014; Gubert, et al. 2016; 
Suadicani, et al. 2006). 
Beyond phenotypes frequently associated with 
mania like changes in motor function and hyperactivity, 
another alternative has been to explore circadian 
rhythms using KO models. There is no doubt that 
irregularities in hormones, sleep cycles, and 
chronotypical variations are closely related to the 
expression of mania. Therefore, the proteins involved 
in the molecular clock have become a therapeutic 
target in murine models. The Clock knockout has 
allowed the identification of the functional 
consequences of some polymorphisms in the genes 
that regulate the molecular pathways of circadian 
rhythms. In the case of Per1 (one of the CLOCK genes), 
the variant 3111T/C alters transcriptional efficiency and 
therefore the physiological processes that control 
sleep-wake dynamics, body temperature, and the 
hormonal changes related to the molecular clock 
(Ozburn, et al. 2016). 
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Figure 1. Most-used KO animal models in mania (blue), domains (red) and phenotypic related subdomains (black) 
 
 
Although some animal models, particularly KO, 
are not considered explicit animal models by many 
researchers, they have helped select molecular targets 
that underlie the complex expression of mania in 
humans. However, the weakness of this model lies in 
the difficulty of standardizing the expression of a 
behavior. For example, increased motor activity or 
hyperactivity as an exclusive condition for mania that 
with difficulty emulates the presence of an episode of 
extreme irritability, uninhibited behavior, or even 
behavioral disorganization. Therefore, the use of 
consanguineous mice or any genetically modified 
animal cannot itself constitute a standard comparative 
animal model of the expression of behaviors of interest 
in mania. Underlying these behaviors is the 
participation of various widely-distributed molecular 
targets that produce an incalculable number of results 
that have not been consistently replicated in the 
etiopathogenesis of the manic spectrum. 
Additionally, due to the methodological 
limitations and costs associated with the use of KO 
models, researchers have used stocks of non-
consanguineous animals, which are much cheaper 
than consanguineous lines and allow for the control of 
the endogamy rate, which shouldn’t exceed 1% per 
generation (Festing 1993). One of the most popular 
mice colonies for this research has been the Black 
Swiss, which has been used to model behavior 
repertories like reward-seeking, risk-taking behavior, 
aggression, hypersexuality, hedonia-like behavior, 
inattention, and the response to psychostimulant drugs. 
These stocks have also been used to explore 
cognitive repertories which manifest deficits in inhibitory 
control, observable through measurements of the 
startle response (SR) and prepulse inhibition (PPI) 
paradigms (Sanchez-Morla, et al. 2016). These have 
been evaluated with non-consanguineous mice as an 
alternative way to trace nuclear psychophysiological 
matrices within the cognitive phenotype and to explain 
the evolution of clinical variables in mania. One 
example that is relatively parsimonious is the activation 
of the sensory-motor response mediated by emotional 
valences as a strategy to refine behavior observation 
(Levin, et al. 2011; Ong, et al. 2005; van Enkhuizen, et 
al. 2015). 
SR is the fastest activated reaction of human 
and animal motor systems, and PPI is one of the 
mechanisms that regulates it. The SR that comes from 
an involuntary activation of the motor tract, with origins 
in the encephalic trunk and whose response and 
latency magnitude has shown intraindividual variation, 
where women manifest a greater SR than men, 
probably depending on sensorial entry (Kofler, et al. 
2001). 
In this context for different mania subtypes, the 
most important aspect to consider about the modulation 
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of RS may be PPI because it controls or restricts access 
to information about irrelevant stimuli and it gives a 
cognitive hierarchy to the information that enters, 
facilitating the sequence and planning of behavior 
(Blumenthal, et al. 1996). For now, one of the 
experimental approaches to SR-PPI, through which we 
get most of our information about the neurobiology of 
sensory-motor responses, comes from the acoustic 
startle response (ASR) (Koch 1999). 
In this context, PPI deficits, particularly of the 
acoustic type, have been associated with the manic 
spectrum (Douma, et al. 2014). Undoubtedly the stock 
of non-consanguineous animals helps to determine 
their success as psychophysiological markers of 
trait/state, and mark the neuropathophysiological 
pathways that are potentially involved in the expression 
of mania. Along with SR changes and PPI modulation, 
other behavioral repertories like reward- and sensation-
seeking can be expressed differently in mania, 
suggesting responses that are neurophysiologically 
different according to the manic subtype (see figure 2).  
Responses to the three most prevalent 
behavioral patterns in mania have been modeled in 
mice: irritability, a domain related to resident intruder 
which is observable in approximately 70% of patients; 
hyperactivity, which is present in 90% of manic states 
and is modeled in animals through the increase in 
motor activity; and sleep deprivation, common in 80% 
of patients in the manic phase (Goodwin FK and 2007; 
Young, et al. 2011). With all of these findings, the use 
of non-consanguineous mice has failed to establish a 
robust model approximating the manic spectrum, and 
there are still limitations in modeling the putative 
neuropathophysiological signals that operate in mania. 
The use of mice to model behavior is not 
specific to mania, and most evaluated behavioral 
repertories are inherent to several mental disorders. 
This suggests distinct etiopathogenic pathways. For 
example, one of the most sensitive models to simulate 
mania in mice has been the sensitization model 
mediated by psychostimulants, which produces 
psychomotor agitation and hyperactivity. However, this 
is not exclusive to mania, because the intermittence of 
manic episodes suggests additional mechanisms 
involving other neurochemical pathways along with the 
increase and reuptake of dopamine generated by the 
psychostimulant. 
Given the lack of consistency of some of the 
behavior signs in the use of these models and in the 
subtypes of mania, different studies have tried to outline 
an experimental path that discriminates between 
different cortical areas and cognitive dysfunction, 
principally that which is most frequently observable in 
the manic spectrum as performance in executive 
function, attention, verbal fluency, and work memory. 
Approaching a neurofunctional representation of the 
cortical regions associated with these cognitive 
functions, especially the dorsolateral prefrontal, 
anterior cingulate, parietal, and temporal, has allowed 
the construction of a neurophysiological and molecular 
network to explain the differential expressions of the 
cognitive disturbances observable in mania. 
On this question, Ersland et al. found similar 
functional annotations for homologous genes in 
humans and rats in frontal and temporal areas which 
could give functional clues to cellular communication 
mechanisms, intracellular signaling cascades, signal 
transduction, emryogenesis, and neurogenesis, 
potentially associated with cognitive dysfunction in 
mania (Ersland, et al. 2012; Le-Niculescu, et al. 2009). 
For example, changes in the expression of the brain-
derived neurotrophic factor (Bdnf) in mice are 
associated with deterioration in work memory and 
present dorsolateral correlation. In the same way, Dbp 
(D-box binding protein) and Per1 (period circadian 
protein homolog 1) genes involved in the circadian 
rhythm and prefrontal correlation suggest a singular 
etiopathogenic pathway in the expression of subtypes 
in mania (Stansberg, et al. 2011). 
 
Figure 2. Most-used physiological and behavioral patterns 
to model different subtypes in mania with the use of non-
consanguineous mice. 
 
 
While comparisons between humans and mice 
could generate methodological bias because of the 
difference in size, connectivity, and cortical areas, 
some patterns of cortical organization are relatively 
universal among major mammal groups. Zones of great 
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cortical similarity can be observed particularly in the 
primary auditory area and the primary and secondary 
visual areas, in part because of the expression of 
common inheritable genetic patterns among all 
mammals. From this reference point, recent findings 
have been able to identify some common genetic 
patterns between rodents and humans that allow the 
recognition of differential functional specialization in 
both species (Chen, et al. 2011). 
Additionally, for mania subtypes, altered or 
differential protein expression in some zones of the 
brain involved in the phenotype of interest could favor 
the development of strains or lines of animals in which 
molecular changes that have previously been observed 
in those individuals that exhibit the manic phenotype 
can be identified. It’s worth noting the need to review 
and verify the validity of the content in constructive and 
predictive terms for these translational approaches. 
For now, and in the interest of deepening the 
mechanisms involved in the etiopathogenesis of mania 
with the use of animal models, several alternatives 
have been proposed: 
 
3. THE INTERNATIONAL CONSORTIUM ON 
LITHIUM GENTICS (CONLIGEN) 
 
Without a doubt lithium sets a putative 
neurobiological pathway for bipolar disorder. Lithium 
has a broad intercellular action mechanism.  It 
regulates the sodium pump (Na+/K+-
adenosintrifosfatasa), acts on G proteins, modulates 
the phosphatidylinositol cycle, and inhibits the adenylyl 
cyclase AMPc system. Because of this, ConLiGen 
came out of the attempts to identify effective 
neuropharmacological targets related to the response 
to lithium in the intervention in bipolar disorder. 
ConLiGen’s main objective is defining the phenotype 
that responds to lithium, analyzing its pharmacogenetic 
aspects and also limiting its adverse effects, while 
keeping in mind the differential genetic susceptibility 
(due to the populational ethnic component). 
Currently three genome-wide association 
studies (GWAS) have been performed. Their findings 
have not been consistently replicated, probably due to 
the genetic heterogeneity of the populations from which 
patients were recruited, small sample sizes, and 
possibly the use of different clinical protocols to define 
the phenotype. ConLiGen recently published a GWAS 
on lithium response in approximately 2500 patients, 
using rigorous scales for clinical evaluation, controlling 
interevaluator reliability and applying ancestry controls 
in the sample, allowing them to identify long non-coding 
RNA sequences (lncRNA) (Hou, et al. 2016). 
LncRNAs could act as regulators of genetic 
expression though a series of mechanisms like 
chromatin modifications, the increase of the 
transcription and degradation of mRNA. These findings 
need to be replicated to begin functional genomic 
studies. However, they contribute to deciphering the 
fundamental molecular pathways in those patients with 
good therapeutic responses to lithium as one of the 
clinical subtypes of bipolar disorder. The recognition of 
highly-conserved cellular processes that we share with 
mice brings about the need to evaluate the 
mechanisms involved in the response to lithium in 
animal models. The findings obtained by ConLiGen 
generate alternative ways to model new therapeutic 
targets and the experimental use of mice would refine 
these findings. 
 
4. MODELLING NEUROPROGRESSION IN 
MANIA 
 
Evaluating the evolution of mania through time 
is a challenge for phenomics.  The phenomenology of 
mania establishes particular subtypes of progression, 
namely: higher episode frequency; decrease in the 
interval between episodes; negative evolution in the 
response to treatment; and progressive and variable 
evolution in neurocognitive deterioration. These 
combine with structural changes in some regions of the 
brain. An experimental model to determine the 
neuroprogression of recurrent mania in mice could 
trace putative pathophysiological pathways in mania 
(Sharma, et al. 2016). An example of this would be the 
controlled exposure for temporary intervals to a 
psychostimulant or domaminergic inhibitor, promoting 
the expression of behavior responses that correlate 
with the neuroprogression of mania in humans. 
 
5. THE USE OF DESIGNER RECEPTORS 
EXCLUSIVELY ACTIVATED BY DESIGNER 
DRUGS (DREADDS) 
 
The lack of robust technology, reversibility, and 
special-temporal control has limited the consistency of 
behavior studies in comparative biology. Consequently, 
the recognition of how molecular and neurochemical 
networks mediate the expression of behavioral patterns 
in both a short (minutes to hours) and long (days to 
weeks) time reference constitutes a challenge in 
modelling behaviors associated with mental illnesses in 
periods of evolution, change and maintenance of 
conduct, due to spatiotemporal limitations. 
The use of DREADDs allows the 
pharmacological activation or inhibition of specific 
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neuronal groups through signaling pathways coupled 
with G proteins. (Urban, et al. 2016). This 
neuropharmacological mechanism, which uses 
modified protein receptors, has applications for 
psychiatry and animal models. 
In mania, one of the phenotypes frequently 
associated with mice has been the increase of motor 
activity. In this case, DREADDs help to explain 
behavioral repertories in congruence with the activation 
of molecular receptors and the characterization of brain 
circuits in a given brain topology.  Currently, DREADDs 
are an excellent strategy for behavior studies in animal 
models to evaluate the prolonged effect of neuronal 
activation or inhibition (Aston-Jones and Deisseroth 
2013; Farrell and Roth 2013), potentially associated 
with the manifestation of behavior related to the manic 
spectrum. They also facilitate the determination of the 
functional consequences of the activation of neuronal 
pathways limited to mania. 
 
6. IMPLEMENT CONVERGENT FUNCTIONAL 
GENOMICS 
 
With the development of the functional 
genomics and the recognition of gene sequences and 
function, along with the recent findings in comparative 
genomics (Yue, et al. 2014), it has been determined 
that mice and humans share approximately 70% of the 
protein-producing sequences in 1.5% of their 
respective genomes.  Yue et al. found significant 
correlations for both species in histone modification that 
suggest critical regions related to neurological 
diseases, particularly bipolar disorder. 
It is precisely these results of conserved gene 
expression conserved between animals and humans 
that support the development of translational 
methodologies like Convergent Functional Genomics 
(CFG), which integrates Bayesian approaches to 
evaluate shared patterns in animal models that 
converge with human beings. While research on bipolar 
disorder in humans has evolved to refine diagnostic 
processes that contribute to clinical specificity in mania, 
the parallel use of animal models has contributed to 
improving molecular sensitivity. Therefore, CFG 
incorporates gene expression profiles in animals, which 
along with human genetic linkage studies promote 
efficient alternatives in clonal positioning, outlining 
molecular targets that are relevant to disease 
pathophysiology (Le-Niculescu, et al. 2008; Niculescu 
2013). 
 
 
7. OPTOGENETICS 
 
Following the discoveries of neurobiological 
pathways that were articulated by comparative 
genomics and traslational function, the development of 
tools that allow the real-time manipulation of neuronal 
activity in relevant neurophysiological zones has 
become a crucial experimental methodology for the 
recognition of the modulation of neural circuits and their 
temporal variation, promoting the identification of 
molecular signals of cellular regulation (Sidor and 
McClung 2014). Optogenetics also allows the analysis 
of reaction times in the modulation of neural circuits in 
the expression of a behavior, through the analysis of 
distribution entropy, similar to analyses performed in 
thermodynamics. This analysis contributes to 
explaining how the expression of a behavioral pattern 
is the reflection of the duration of cognitive processes 
involved in it (Hong and Newell 2008; Mesik, et al. 2015; 
Rossi, et al. 2012). It also allows the identification of 
dysfunctional behavioral patterns in the manic 
spectrum in terms of intensity, duration or chronicity, 
and shows the cortical neuroarchitecture and molecular 
pathways most likely associated with the behavior of 
interest. 
Finally, although animal models have led to 
progress in the clinical modeling of mania, the results 
of molecular pathways that provide relevant 
pharmacogenetic insights and facilitate the 
discrimination of differential clinical patterns have still 
not been determined. Mania includes several clinical 
subtypes that also interact with changes related to early 
or late onset, a greater or lesser number of crises in a 
given time frame, and the severity and temporary 
progression of intercrisis. Furthermore, each subtype 
can be associated with different physiopathological 
correlations, which simultaneously are related to 
molecular bases and distinct genetics, which could 
configure an intermediate phenotype or 
endophenotype. The challenge in using non-
consanguineous stocks of animals is to always 
supervise the protocols of content validation, 
construction, and prediction in the evaluation of the 
behavior to model. On the other hand, although the use 
of consanguineous lines as animal models is 
controversial, they have been advantageous because 
they reduce the genetic heterogeneity in comparative 
analyses, simplifying the identification of profiles with 
expressions in common. This is now possible due to 
recent results that determined the conserved and 
shared regions between mice and humans. 
Perspectives like optogenetics are the future 
for the study of the brain. Understanding the changes 
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in neuronal activity that occur in days and weeks in the 
development of a psychiatric disorder contributes to the 
determination of which circuits underlie the 
phenotypical expression relevant to the manic 
spectrum. Some preliminary studies are directed at 
studying circadian rhythms and how cortical reward is 
influenced by alterations in daily activities that refer the 
activity to a specific neural circuit related to the activity 
of dopamine in the mesolimbic pathway (Sidor and 
McClung 2014), demonstrating behaviors in mice that 
are belong to the expression of mania in humans. 
However, to overcome experimental difficulties, 
Optogenetics as a discipline still requires advances in 
the thermodynamic stability of proteins and to be able 
to refine the association of neuronal networks and the 
expression of behavioral patterns in psychiatric 
illnesses.  
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